Olympus’s Odin Medical wins FDA Clearance for its Caddie computer-aided detection (CADe) device

WT default author logo
Women's Tabloid News Desk
Picture of Women's Tabloid News Desk
Women's Tabloid News Desk

Olympus’s Odin Medical bags FDA 510(k) clearance for its Caddie computer-aided detection (CADe) device. It’s a cloud-based AI that helps gastroenterologists find suspected colorectal polyps during a colonoscopy. Olympus states that this is the first cloud-based AI technology for this purpose. It might even compete with the Medtronic AI-supported GI Genius platform. 

“Together with Olympus, we are proud to bring this groundbreaking technology to the U.S.,” Odin Vision CEO Peter Mountney said. “The cloud gives us the ability to keep hospitals up-to-date with advances in AI and gives peace of mind to doctors that they can easily access current technology for their patients.”

Caddie is a system that processes colonoscopy videos in real-time and uses visual cues to inform the endoscopists of possible polyps. Then the endoscopist reviews the areas Caddie has flagged as potential polyps and determines the results.

One of Olympus’s goals is to make colonoscopy, the gold standard of colorectal screening, more effective. It is the company’s wish that they can lighten the social burden of deaths from colorectal cancer. According to them, their Olympus Intelligent Endoscopy Ecosystem utilizing Caddie could support and make clinical decision-making more accurate in that area.

“As a global leader in endoscopy, it is our vision to make AI a key component of our digital transformation. Odin’s success with this FDA clearance is an important step forward. A digitally transformed endoscopy ecosystem has the potential to support doctors and hospitals as they navigate global industry megatrends like cost pressures and staff shortages, in the context of an aging population,” said Miquel Àngel García, global head of Endoscopy Solutions Ecosystem at Olympus Corporation. “We are very excited about the huge opportunities for patients and healthcare systems that these advancements make possible.”

Share:

Related Insights

AstraZeneca commits $15 billion investment in China through 2030 to expand R&D and manufacturing

WellTheory launches postpartum program for women managing autoimmune symptoms after childbirth

King’s College London – Jeddah to Launch the First Saudi Conference on Gynecology and Fertility Tomorrow

Origin secures Series B funding to expand pelvic floor physical therapy access

Sword Health acquires Kaia Health in $285 million deal to expand in US and Germany

Wellspect HealthCare launches Surity™ Female External Catheter in the United States

Evaro secures $25 million series A to scale embedded healthcare platform in the UK

Aviva Bio receives FDA guidance on women’s testosterone therapy and reports new AVA-291 safety data